Needham initiated coverage of ICU Medical with a rating of Hold
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/14/2024 | $183.00 | Hold | Jefferies |
| 6/21/2024 | Hold | Needham | |
| 6/17/2024 | $135.00 | Mkt Perform → Outperform | Raymond James |
| 11/8/2022 | Outperform → Mkt Perform | Raymond James | |
| 2/28/2022 | $286.00 → $265.00 | Outperform | Raymond James |
| 10/22/2021 | $302.00 → $280.00 | Overweight | Keybanc |
| 9/9/2021 | $220.00 → $286.00 | Outperform | Raymond James |
| 9/9/2021 | $225.00 → $302.00 | Overweight | Keybanc |
The partnership creates one of the largest global IV solutions manufacturing networks with combined production of an estimated 1.4 billion annual units and aims to bring additional supply chain resiliency and new innovation to the North American IV solutions market. Joint venture becomes part of a global manufacturing network with scale and redundancyIntends to add long-term supply resiliency and accelerate IV solutions new product development in North AmericaCombines Otsuka Pharmaceutical Factory, Inc.'s expertise and global manufacturing scale with ICU Medical's strong North American production and distributionICU Medical to provide commercial services to the joint ventureExpected to becom
SAN CLEMENTE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended September 30, 2024. Third Quarter 2024 Results Third quarter 2024 revenue was $589.1 million, as compared to $553.3 million in the same period in the prior year. GAAP gross profit for the third quarter of 2024 was $204.9 million, as compared to $183.9 million in the same period in the prior year. GAAP gross margin for the third quarter of 2024 was 34.8%, as compared to 33.2% in the same period in the prior year. GAAP net loss for the third quarter of 2024
SAN CLEMENTE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- ICU Medical (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced that Company management will present at the UBS Global Healthcare Conference being held in Rancho Palos Verdes, California, November 11-14, 2024. ICU Medical's presentation will be on Wednesday, November 13, 2024 at 4:15 p.m. PT (7:15 p.m. ET). Company management will also be participating in one-on-one meetings on Wednesday, November 13, 2024. The presentation will be webcast live and can be accessed by going to the Company's website at http://www.icumed.com, clicking on the Investors tab and clicking on the E
Jefferies initiated coverage of ICU Medical with a rating of Hold and set a new price target of $183.00
Needham initiated coverage of ICU Medical with a rating of Hold
Raymond James upgraded ICU Medical from Mkt Perform to Outperform and set a new price target of $135.00
NEW YORK, Nov. 27, 2023 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600 effective prior to the open of trading on Thursday, November 30: Carlyle Group Inc. (NASD: CG) will replace ICU Medical Inc. (NASD: ICUI) in the S&P MidCap 400. ICU Medical will replace PacWest Bancorp (NASD: PACW) in the S&P SmallCap 600. Banc of California Inc. (NYSE:BANC) is acquiring PacWest Bancorp in a deal expected to be completed soon, pending final closing conditions. Post-merger, Banc of California will remain in the S&P SmallCap 600. ICU Medical is more representative of the small-cap market space.WP Carey Inc. (NYSE: WPC) will replace Worthingt
10-Q - ICU MEDICAL INC/DE (0000883984) (Filer)
8-K - ICU MEDICAL INC/DE (0000883984) (Filer)
8-K - ICU MEDICAL INC/DE (0000883984) (Filer)
4 - ICU MEDICAL INC/DE (0000883984) (Issuer)
4 - ICU MEDICAL INC/DE (0000883984) (Issuer)
4 - ICU MEDICAL INC/DE (0000883984) (Issuer)
SAN CLEMENTE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended September 30, 2024. Third Quarter 2024 Results Third quarter 2024 revenue was $589.1 million, as compared to $553.3 million in the same period in the prior year. GAAP gross profit for the third quarter of 2024 was $204.9 million, as compared to $183.9 million in the same period in the prior year. GAAP gross margin for the third quarter of 2024 was 34.8%, as compared to 33.2% in the same period in the prior year. GAAP net loss for the third quarter of 2024
SAN CLEMENTE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its third quarter 2024 earnings release and conference call. The Company will release its third quarter 2024 results on Tuesday, November 12th, 2024 at approximately 4:00 p.m. ET (1:00 p.m. PT) and will be conducting a conference call concerning those results at 4:30 p.m. ET (1:30 p.m. PT) on Tuesday, November 12th, 2024. The call can be accessed at (800) 343-5172, conference ID "ICUMED". The conference call will be simultaneously available by webcast, which can be accessed by going to the Com
SAN CLEMENTE, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended June 30, 2024. Second Quarter 2024 Results Second quarter 2024 revenue was $596.5 million, compared to $549.3 million in the same period in the prior year. GAAP gross profit for the second quarter of 2024 was $207.4 million, as compared to $192.3 million in the same period in the prior year. GAAP gross margin for the second quarter of 2024 and 2023 was 35%. GAAP net loss for the second quarter of 2024 was $(21.4) million, or $(0.88) per diluted share, as c
Submission status for ICU MEDICAL INC's drug POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER (SUPPL-8) with active ingredient POTASSIUM CHLORIDE; SODIUM CHLORIDE has changed to 'Approval' on 05/15/2023. Application Category: ANDA, Application Number: 078446, Application Classification: Labeling
SC 13G/A - ICU MEDICAL INC/DE (0000883984) (Subject)
SC 13G/A - ICU MEDICAL INC/DE (0000883984) (Subject)
SC 13D/A - ICU MEDICAL INC/DE (0000883984) (Subject)
Needham analyst Mike Matson initiates coverage on ICU Medical (NASDAQ:ICUI) with a Hold rating.
Raymond James analyst Jayson Bedford upgrades ICU Medical (NASDAQ:ICUI) from Market Perform to Outperform and announces $135 price target.
U.S. stocks were mixed, with the Dow Jones gaining around 100 points on Thursday. Shares of Spectrum Brands Holdings, Inc. (NYSE:SPB) rose sharply during Thursday's session following upbeat earnings. Spectrum Brands posted adjusted earnings of $1.62 per share, beating expectations of 62 cents per share. The company's quarterly sales came in at $718.50 million versus estimates of $707.52 million, according to data from Benzinga Pro. Spectrum Brands shares surged 12.4% to $95.00 on Thursday. Here are some other big stocks recording gains in today's session. Sezzle Inc. (NASDAQ:SEZL) shares climbed 69.9% to $75.99 after the company reported a year-over-year increase in first-qu